158 related articles for article (PubMed ID: 36143940)
21. CYP4Z1 3'UTR represses migration of human breast cancer cells.
Wang B; Zheng L; Chou J; Li C; Zhang Y; Meng X; Xi T
Biochem Biophys Res Commun; 2016 Sep; 478(2):900-7. PubMed ID: 27520371
[TBL] [Abstract][Full Text] [Related]
22. HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer.
Wang Y; Sun J; Li N; Che S; Jin T; Liu S; Lin Z
J Ovarian Res; 2017 Apr; 10(1):26. PubMed ID: 28388957
[TBL] [Abstract][Full Text] [Related]
23. The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
Zheng L; Li X; Gu Y; Lv X; Xi T
Breast Cancer Res Treat; 2015 Feb; 150(1):105-18. PubMed ID: 25701119
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, metabolism and off-target effects in the rat of 8-[(1H- benzotriazol-1-yl)amino]octanoic acid, a selective inhibitor of human cytochrome P450 4Z1:
Kowalski JP; Pelletier RD; McDonald MG; Kelly EJ; Rettie AE
Xenobiotica; 2021 Aug; 51(8):901-915. PubMed ID: 33993844
[TBL] [Abstract][Full Text] [Related]
25. HET0016 attenuates the stemness of breast cancer cells through targeting CYP4Z1.
Liu H; Qin H; Zhou Y; Yuan Y; Liu Y; Chen Y; Yang Y; Ni H; Xi T; Zheng L
Mol Carcinog; 2021 Jun; 60(6):413-426. PubMed ID: 33866606
[TBL] [Abstract][Full Text] [Related]
26. Competing endogenous RNA networks of CYP4Z1 and pseudogene CYP4Z2P confer tamoxifen resistance in breast cancer.
Zheng L; Li X; Meng X; Chou J; Hu J; Zhang F; Zhang Z; Xing Y; Liu Y; Xi T
Mol Cell Endocrinol; 2016 May; 427():133-42. PubMed ID: 26980484
[TBL] [Abstract][Full Text] [Related]
27. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
[TBL] [Abstract][Full Text] [Related]
28. NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.
Shi C; Qin L; Gao H; Gu L; Yang C; Liu H; Liu T
Tumour Biol; 2017 Sep; 39(9):1010428317714631. PubMed ID: 28877654
[TBL] [Abstract][Full Text] [Related]
29. High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer.
Tan L; Sha L; Hou N; Zhang M; Ma Q; Shi C
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31152111
[TBL] [Abstract][Full Text] [Related]
30. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans.
Khayeka-Wandabwa C; Ma X; Cao X; Nunna V; Pathak JL; Bernhardt R; Cai P; Bureik M
Int Immunopharmacol; 2019 Aug; 73():64-71. PubMed ID: 31082724
[TBL] [Abstract][Full Text] [Related]
31. High Expression of RING Finger Protein 126 Predicts Unfavorable Prognosis of Epithelial Ovarian Cancer.
Wang C; Wen A; Qiao J; Liu Y; Guo Y; Wang W
Med Sci Monit; 2020 Apr; 26():e921370. PubMed ID: 32254065
[TBL] [Abstract][Full Text] [Related]
32. The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
Alnabulsi A; Swan R; Cash B; Alnabulsi A; Murray GI
Br J Cancer; 2017 Jun; 116(12):1612-1620. PubMed ID: 28557975
[TBL] [Abstract][Full Text] [Related]
33. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
34. Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid.
Zöllner A; Dragan CA; Pistorius D; Müller R; Bode HB; Peters FT; Maurer HH; Bureik M
Biol Chem; 2009 Apr; 390(4):313-7. PubMed ID: 19090726
[TBL] [Abstract][Full Text] [Related]
35. [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
Qiao YH; Cheng J; Guo RX
Zhonghua Fu Chan Ke Za Zhi; 2007 May; 42(5):325-9. PubMed ID: 17673045
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
37. The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer.
Li C; Zheng L; Xin Y; Tan Z; Zhang Y; Meng X; Wang Z; Xi T
FEBS Lett; 2017 Apr; 591(7):991-1000. PubMed ID: 28236635
[TBL] [Abstract][Full Text] [Related]
38. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
39. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases.
Tradonsky A; Rubin T; Beck R; Ring B; Seitz R; Mair S
Am J Clin Pathol; 2012 Jun; 137(6):918-30. PubMed ID: 22586051
[TBL] [Abstract][Full Text] [Related]
40. Conditional regulation of the human CYP4X1 and CYP4Z1 genes.
Savas U; Hsu MH; Griffin KJ; Bell DR; Johnson EF
Arch Biochem Biophys; 2005 Apr; 436(2):377-85. PubMed ID: 15797250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
